
Novartis invests €100 million to expand French manufacturing plant
pharmafile | August 15, 2016 | News story | Manufacturing and Production, Sales and Marketing | Novartis, manufacturing
Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of Biotechnology facility with a €100 million investment over four years.
The facility manufactures a range of active ingredients including asthma and psoriasis treatments, anti-rejection drugs for kidney transplantation and an anti-inflammatory agent. The expansion will add a second purification line and several cell culture bioreactors to what the Swiss biopharma calls ‘the crown jewel in Novartis’ monoclonal antibody bioproduction sites for the global market.’ The new production equipment is expected to be in place by January 2017 with commercial activities starting by the end of 2018.
The decision was originally made in April to meet increasing demand for the company’s biopharmaceuticals. The expansion hopes to increase production at the facility by 70% and add 100 new jobs to the already 430-strong workforce by 2020.
Matt Fellows
Related Content

BioDuro establishes joint manufacturing venture with Cenra
BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …





